Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease

NeuroSignals

Volumn 11, Issue 5, 2002, Pages 293-297

  Pasinetti, Giulio Maria ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloidosis; Cell cycle; Cyclooxygenase 2; Inflammation

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN SYNTHASE; SULINDAC; AMYLOID BETA PROTEIN; CELL RECEPTOR; NEUROPROTECTIVE AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DNA MICROARRAY; EARLY DIAGNOSIS; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HIPPOCAMPUS; HUMAN; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; INFLAMMATION; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL CYCLE; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; NEUROPROTECTIVE AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036770205     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067428     Document Type: Review

References (43)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
2. Vandenabeele P, Fiers W: Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol Today 1991;12:217-219.
3. Pasinetti GM: Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system. Neurobiol Aging 1996;17:707-716
4. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 1997;18:415-421.
5. Oda T, Lehrer-Graiwer J, Finch CE, Pasinetti GM: Complement and beta-amyloid neurotoxicity in vitro: A model for Alzheimer disease. Alzheimers Res 1995;1:29-34.
6. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993;90:10061-10065.
7. Pasinetti GM, Aisen PS: Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87: 319-324.
8. Ho L, Pieroni C, Winger D, Purohit DP, Aisen P, Pasinetti GM: Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 1999;57:295-303.
9. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK: Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999;58:1135-1146.
10. Aisen PS: Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontology 1997;43:143-149.
11. Pasinetti GM: Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions. J Neurosci Res 1998;54:1-6.
12. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM: Cytokine gene expression as a function of the clinical progression of Alzheimer's disease dementia. Arch Neurol 2000;57:1153-1160.
13. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, Buxbaum JD, Aisen PS, Pasinetti GM: Neuronal cyclooxygenase 2 is a marker of progression of early Alzheimer's disease. Arch Neurol 2001;58:487-492.
14. Xiang Z, Pasinetti GM: HLA-DR microglia immunodetection in brain as a function of the clinical progression of Alzheimer's disease dementia. Submitted.
15. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-432.
16. In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
17. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P: Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
18. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201
19. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-593.
20. Sainati S, Ingram D, Talwalker S, Geis G: Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease (abstract 180). 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, 2000.
21. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC: Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998;55:1185-1191.
22. Katori M, Majima M: Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000;49:367-392.
23. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU: A subset of NSAIDs lower amyloidogenic A β1-42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
24. Xiang Z, Ho L, Yemul S, Zhao Z, Pompl P, Kelley K, Dang A, Teplow D, Pasinetti GM: Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr 2002;10:271-278.
25. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
26. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA: Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 2000;61:128-133.
27. Mirjany M, Ho L, Pasinetti GM: Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate mediated excitotoxicity. J Pharmacol Exp Ther 2002;301:494-500.
28. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelly K, Spielman L, Aisen PS, Pasinetti GM: Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 2002;23:327-334.
29. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA: Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 1997;150:1933-1939.
30. Shiff SJ, Koutsos MI, Qiao L, Rigas B: Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp Cell Res 1996;222:179-188.
31. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
32. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
33. Landreth GE, Heneka MT: Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 2001;22:937-944.
34. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN: Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 2002;61:7-12.
35. Kitamura Y, Shimohama S, Koike H, Kakimura J, Matsuoka Y, Nomura Y, et al: Increased expression of cyclooxygenases and peroxisome proliferator- activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 1999;254:582-586.
36. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
37. Bidaut-Russell M, Gabriel MR: Adverse gastrointestinal effects of NSAIDs: Consequences and costs. Best Pract Res Clin Gastroenterol 2001;15:739-753.
38. Smalley WE, Griffin MR: The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-396.
39. Sturkenboom MC, Romano F, Simon G, Correa-Leite ML, Villa M, Nicolosi A, et al: The iatrogenic costs of NSAID therapy: A population study. Arthritis Rheum 2002;47:132-140.
40. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000;284:1247-1255.
41. Aisen PS, Schmeidler J, Pasinetti GM: Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002;58:1050-1054.
42. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model 2002;20:359-371.
43. Hinz B, Brune K: Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002;300:367-375.